TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06976268: A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Sponsor: Biohaven Therapeutics Ltd. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 550 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,408,192

Rescue Site Savings

+$2,272,128

Unlock Full NCT06976268 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06976268 Rescue Dossier →